title: [Comparison of unidimensional and bidimensional measurement to assess therapeutic response in the treatment of solid tumors].
abstract: OBJECTIVE
  In this prospective study we applied both the bidimensional WHO method and the unidimensional RECIST method in treatment follow-up of solid tumors.
  
  
  METHODS
  Computed tomography was performed in 80 patients before and after one chemotherapy cycle: 20 patients each with lung cancer, lymphoma, and metastases of the lung and the liver. In 207 tumor lesions unidimensional and bidimensional measurements were performed: 36 lesions of lung cancer, 51 lesions of lymphoma, and 60 lesions of metastases of the lung and the liver, respectively. We assigned the results to the corresponding response categories.
  
  
  RESULTS
  For tumor assessment, the kappa statistic produced a high agreement of 0.94 between the two methods for assessment of therapeutic response.
  
  
  CONCLUSIONS
  The unidimensional RECIST measurement is easier to perform in order to assess tumor size during treatment follow-up in oncologic radiology.
authors.affiliation: Institut für Diagnostische und Interventionelle Radiologie und Neuroradiologie, Universitätsklinikum, Essen. elke.hauth@uni-essen.de
authors.forename: E A M
authors.initials: EA
authors.lastname: Hauth
authors.forename: J
authors.initials: J
authors.lastname: Stattaus
authors.forename: M
authors.initials: M
authors.lastname: Forsting
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000465:Algorithms; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000000981:diagnostic imaging* / Q000188:drug therapy*; D017063:Outcome Assessment, Health Care / Q000379:methods*; D011857:Radiographic Image Interpretation, Computer-Assisted / Q000379:methods*; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D014057:Tomography, X-Ray Computed / Q000379:methods*; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents